Concepts (201)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 4 | 2018 | 412 | 1.030 |
Why?
|
| Biopsy | 6 | 2018 | 457 | 0.700 |
Why?
|
| Reading | 6 | 2012 | 94 | 0.530 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2016 | 4 | 0.510 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2016 | 8 | 0.510 |
Why?
|
| Semantics | 5 | 2013 | 57 | 0.500 |
Why?
|
| Histiocytosis | 1 | 2016 | 4 | 0.500 |
Why?
|
| Histiocytes | 1 | 2016 | 6 | 0.500 |
Why?
|
| Lymphatic Vessels | 1 | 2016 | 32 | 0.470 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 165 | 0.450 |
Why?
|
| Emotions | 6 | 2018 | 229 | 0.440 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 361 | 0.390 |
Why?
|
| Biomarkers, Tumor | 5 | 2018 | 525 | 0.380 |
Why?
|
| Sarcoma, Kaposi | 1 | 2010 | 17 | 0.320 |
Why?
|
| Immunohistochemistry | 5 | 2018 | 906 | 0.310 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 720 | 0.300 |
Why?
|
| Attention | 4 | 2012 | 150 | 0.270 |
Why?
|
| Vocabulary | 3 | 2013 | 20 | 0.270 |
Why?
|
| Fixation, Ocular | 3 | 2012 | 33 | 0.250 |
Why?
|
| AIDS-Associated Nephropathy | 2 | 2016 | 9 | 0.240 |
Why?
|
| Reaction Time | 7 | 2013 | 128 | 0.230 |
Why?
|
| Psycholinguistics | 4 | 2018 | 36 | 0.230 |
Why?
|
| Kidney Failure, Chronic | 3 | 2016 | 205 | 0.210 |
Why?
|
| Electroencephalography | 2 | 2008 | 153 | 0.200 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2003 | 6 | 0.200 |
Why?
|
| Concept Formation | 2 | 2013 | 19 | 0.200 |
Why?
|
| Mixed Function Oxygenases | 1 | 2003 | 20 | 0.200 |
Why?
|
| Verbal Learning | 1 | 2003 | 21 | 0.200 |
Why?
|
| Cytoplasmic Granules | 1 | 2003 | 53 | 0.200 |
Why?
|
| Multienzyme Complexes | 1 | 2003 | 88 | 0.190 |
Why?
|
| Smegmamorpha | 1 | 2022 | 1 | 0.190 |
Why?
|
| Mental Recall | 1 | 2003 | 95 | 0.190 |
Why?
|
| Male | 25 | 2020 | 31083 | 0.180 |
Why?
|
| Carcinoma | 2 | 2016 | 130 | 0.170 |
Why?
|
| Female | 20 | 2018 | 34131 | 0.160 |
Why?
|
| Software | 1 | 2023 | 395 | 0.160 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 210 | 0.160 |
Why?
|
| Pemphigus | 1 | 2020 | 14 | 0.160 |
Why?
|
| Mouth Diseases | 1 | 2020 | 14 | 0.160 |
Why?
|
| Humans | 30 | 2023 | 65554 | 0.160 |
Why?
|
| Adult | 15 | 2018 | 17417 | 0.160 |
Why?
|
| Size Perception | 2 | 2009 | 2 | 0.150 |
Why?
|
| Young Adult | 10 | 2019 | 4831 | 0.150 |
Why?
|
| Brain Concussion | 1 | 2019 | 37 | 0.150 |
Why?
|
| Skin Diseases | 1 | 2020 | 83 | 0.140 |
Why?
|
| Adenoma, Pleomorphic | 1 | 2018 | 9 | 0.140 |
Why?
|
| Sports | 1 | 2019 | 98 | 0.140 |
Why?
|
| Margins of Excision | 1 | 2018 | 32 | 0.140 |
Why?
|
| Kidney | 4 | 2016 | 456 | 0.140 |
Why?
|
| Imagination | 1 | 2018 | 7 | 0.140 |
Why?
|
| Aged | 9 | 2020 | 14958 | 0.140 |
Why?
|
| Athletes | 1 | 2019 | 109 | 0.140 |
Why?
|
| Visual Perception | 2 | 2009 | 45 | 0.130 |
Why?
|
| Membrane Proteins | 1 | 2003 | 929 | 0.130 |
Why?
|
| Decision Making | 4 | 2018 | 420 | 0.130 |
Why?
|
| Jaw | 1 | 2016 | 4 | 0.130 |
Why?
|
| Merkel cell polyomavirus | 1 | 2016 | 5 | 0.130 |
Why?
|
| Eyelid Neoplasms | 1 | 2016 | 9 | 0.120 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2016 | 39 | 0.120 |
Why?
|
| Mucins | 1 | 2016 | 27 | 0.120 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2016 | 20 | 0.120 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2016 | 7 | 0.120 |
Why?
|
| Upper Extremity | 1 | 2016 | 55 | 0.120 |
Why?
|
| DNA, Viral | 1 | 2016 | 236 | 0.120 |
Why?
|
| Cognition | 1 | 2019 | 502 | 0.120 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2015 | 94 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 524 | 0.110 |
Why?
|
| Anti-Retroviral Agents | 1 | 2015 | 75 | 0.110 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 351 | 0.110 |
Why?
|
| Alternariosis | 1 | 2014 | 2 | 0.110 |
Why?
|
| Renal Insufficiency | 2 | 2007 | 68 | 0.110 |
Why?
|
| Social Behavior | 1 | 2014 | 90 | 0.100 |
Why?
|
| Saccades | 2 | 2010 | 15 | 0.100 |
Why?
|
| Immunocompromised Host | 1 | 2014 | 109 | 0.100 |
Why?
|
| Antifungal Agents | 1 | 2014 | 135 | 0.100 |
Why?
|
| Leprosy, Borderline | 1 | 2013 | 2 | 0.100 |
Why?
|
| Leprosy, Lepromatous | 1 | 2013 | 2 | 0.100 |
Why?
|
| Tinea Versicolor | 1 | 2013 | 3 | 0.100 |
Why?
|
| Adolescent | 7 | 2019 | 6377 | 0.100 |
Why?
|
| Visual Fields | 2 | 2010 | 51 | 0.090 |
Why?
|
| Treatment Outcome | 4 | 2018 | 5822 | 0.090 |
Why?
|
| Arousal | 3 | 2013 | 43 | 0.090 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 5620 | 0.090 |
Why?
|
| Diagnostic Errors | 1 | 2013 | 105 | 0.090 |
Why?
|
| Kidney Transplantation | 1 | 2014 | 330 | 0.090 |
Why?
|
| Time Factors | 2 | 2016 | 3788 | 0.090 |
Why?
|
| Anticipation, Psychological | 1 | 2010 | 9 | 0.080 |
Why?
|
| Middle Aged | 5 | 2016 | 18277 | 0.080 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2010 | 16 | 0.080 |
Why?
|
| Herpesvirus 8, Human | 1 | 2010 | 17 | 0.080 |
Why?
|
| HIV | 1 | 2010 | 70 | 0.080 |
Why?
|
| Diagnosis, Differential | 3 | 2020 | 998 | 0.080 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2010 | 136 | 0.080 |
Why?
|
| Fovea Centralis | 1 | 2009 | 15 | 0.080 |
Why?
|
| Comprehension | 2 | 2010 | 138 | 0.070 |
Why?
|
| Verbal Behavior | 1 | 2009 | 36 | 0.070 |
Why?
|
| Phosphoproteins | 1 | 2010 | 223 | 0.070 |
Why?
|
| Tuberculosis, Endocrine | 1 | 2008 | 1 | 0.070 |
Why?
|
| Hyperparathyroidism | 1 | 2008 | 8 | 0.070 |
Why?
|
| Parathyroid Diseases | 1 | 2008 | 3 | 0.070 |
Why?
|
| HIV Infections | 1 | 2015 | 965 | 0.070 |
Why?
|
| Visual Acuity | 1 | 2009 | 134 | 0.070 |
Why?
|
| Evoked Potentials | 1 | 2008 | 39 | 0.070 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 2009 | 101 | 0.070 |
Why?
|
| Hyperplasia | 2 | 2004 | 90 | 0.060 |
Why?
|
| Leukemic Infiltration | 1 | 2007 | 5 | 0.060 |
Why?
|
| Nephritis, Interstitial | 1 | 2007 | 15 | 0.060 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2007 | 46 | 0.060 |
Why?
|
| Nuclear Proteins | 1 | 2010 | 793 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2004 | 631 | 0.060 |
Why?
|
| Portacaval Shunt, Surgical | 1 | 2004 | 2 | 0.060 |
Why?
|
| Urinary Calculi | 1 | 2004 | 3 | 0.060 |
Why?
|
| Eye Movements | 1 | 2006 | 86 | 0.060 |
Why?
|
| Urinary Bladder | 1 | 2004 | 48 | 0.050 |
Why?
|
| Hematuria | 1 | 2004 | 23 | 0.050 |
Why?
|
| Renal Artery | 1 | 2004 | 36 | 0.050 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2004 | 109 | 0.050 |
Why?
|
| Endocarditis, Bacterial | 1 | 2003 | 37 | 0.050 |
Why?
|
| Rats | 2 | 2004 | 2018 | 0.050 |
Why?
|
| Acclimatization | 1 | 2022 | 11 | 0.050 |
Why?
|
| Urination Disorders | 1 | 2002 | 9 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2004 | 546 | 0.050 |
Why?
|
| Renal Artery Obstruction | 1 | 2002 | 22 | 0.050 |
Why?
|
| Fishes | 1 | 2022 | 22 | 0.050 |
Why?
|
| Heart Atria | 1 | 2003 | 138 | 0.050 |
Why?
|
| Kidney Diseases | 1 | 2004 | 180 | 0.050 |
Why?
|
| Digestive System | 1 | 2002 | 27 | 0.050 |
Why?
|
| Brain Mapping | 1 | 2003 | 241 | 0.050 |
Why?
|
| Staphylococcal Infections | 1 | 2003 | 137 | 0.050 |
Why?
|
| Renal Dialysis | 1 | 2003 | 195 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2002 | 125 | 0.040 |
Why?
|
| Cerebral Cortex | 1 | 2003 | 271 | 0.040 |
Why?
|
| Temperature | 1 | 2022 | 316 | 0.040 |
Why?
|
| Water | 1 | 2022 | 318 | 0.040 |
Why?
|
| Photic Stimulation | 2 | 2012 | 93 | 0.040 |
Why?
|
| Orientation | 2 | 2010 | 26 | 0.040 |
Why?
|
| Myocardium | 1 | 2002 | 298 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2004 | 495 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2012 | 612 | 0.040 |
Why?
|
| Scapula | 1 | 2018 | 10 | 0.040 |
Why?
|
| Military Personnel | 1 | 2019 | 120 | 0.030 |
Why?
|
| Affective Symptoms | 1 | 2018 | 17 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2019 | 410 | 0.030 |
Why?
|
| Incidence | 2 | 2015 | 1410 | 0.030 |
Why?
|
| Animals | 3 | 2022 | 21533 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 2700 | 0.030 |
Why?
|
| Proteinuria | 1 | 2016 | 43 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 198 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2016 | 93 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 2015 | 47 | 0.030 |
Why?
|
| United Kingdom | 1 | 2015 | 85 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2016 | 122 | 0.030 |
Why?
|
| Age Factors | 1 | 2019 | 1592 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2016 | 272 | 0.030 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2014 | 35 | 0.030 |
Why?
|
| Negotiating | 1 | 2013 | 16 | 0.030 |
Why?
|
| Leprostatic Agents | 1 | 2013 | 3 | 0.020 |
Why?
|
| Clofazimine | 1 | 2013 | 5 | 0.020 |
Why?
|
| Hypesthesia | 1 | 2013 | 8 | 0.020 |
Why?
|
| Mycobacterium leprae | 1 | 2013 | 6 | 0.020 |
Why?
|
| Dapsone | 1 | 2013 | 10 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 1114 | 0.020 |
Why?
|
| Rifampin | 1 | 2013 | 25 | 0.020 |
Why?
|
| Contraindications | 1 | 2013 | 52 | 0.020 |
Why?
|
| Minocycline | 1 | 2013 | 28 | 0.020 |
Why?
|
| Delayed Diagnosis | 1 | 2013 | 48 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 2510 | 0.020 |
Why?
|
| Linear Models | 1 | 2013 | 409 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2013 | 274 | 0.020 |
Why?
|
| Disease Progression | 1 | 2016 | 1218 | 0.020 |
Why?
|
| Skin | 1 | 2014 | 424 | 0.020 |
Why?
|
| Risk Factors | 2 | 2016 | 5441 | 0.020 |
Why?
|
| Vision Disparity | 1 | 2009 | 2 | 0.020 |
Why?
|
| Electrooculography | 1 | 2009 | 6 | 0.020 |
Why?
|
| Communication | 1 | 2014 | 593 | 0.020 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2008 | 6 | 0.020 |
Why?
|
| Event-Related Potentials, P300 | 1 | 2008 | 3 | 0.020 |
Why?
|
| Hypercalcemia | 1 | 2008 | 12 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 2008 | 138 | 0.020 |
Why?
|
| Reference Values | 1 | 2006 | 331 | 0.010 |
Why?
|
| Urothelium | 1 | 2004 | 22 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 2004 | 84 | 0.010 |
Why?
|
| Rupture, Spontaneous | 1 | 2004 | 22 | 0.010 |
Why?
|
| Kidney Function Tests | 1 | 2004 | 37 | 0.010 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 1 | 2003 | 4 | 0.010 |
Why?
|
| Angiography | 1 | 2004 | 154 | 0.010 |
Why?
|
| Mitral Valve Stenosis | 1 | 2003 | 16 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2004 | 200 | 0.010 |
Why?
|
| Kidney Cortex | 1 | 2002 | 10 | 0.010 |
Why?
|
| Infarction | 1 | 2002 | 21 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 2002 | 128 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 1172 | 0.010 |
Why?
|
| Pain | 1 | 2004 | 403 | 0.010 |
Why?
|
| Recovery of Function | 1 | 2002 | 295 | 0.010 |
Why?
|
| Aortic Valve Stenosis | 1 | 2003 | 195 | 0.010 |
Why?
|
| Echocardiography | 1 | 2003 | 512 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2004 | 1575 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2004 | 2294 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2004 | 2101 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2004 | 1672 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2004 | 2248 | 0.010 |
Why?
|